Compare EVTL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | IMUX |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.9M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | EVTL | IMUX |
|---|---|---|
| Price | $5.69 | $0.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $13.20 | $6.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 08-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $0.56 |
| 52 Week High | $15.99 | $1.39 |
| Indicator | EVTL | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 36.87 |
| Support Level | $5.60 | $0.66 |
| Resistance Level | $6.19 | $0.70 |
| Average True Range (ATR) | 0.59 | 0.04 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 48.92 | 25.81 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.